# Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)

> **NCT02728089** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 115 (actual)

## Conditions studied

- Urinary Tract Infection (UTI)
- Complicated Urinary Tract Infection
- Pyelonephritis
- Uncomplicated Pyelonephritis

## Interventions

- **DRUG:** MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)

## Key facts

- **NCT ID:** NCT02728089
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-14
- **Primary completion:** 2017-09-05
- **Final completion:** 2017-09-05
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2019-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728089, "Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02728089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*